Menu

Cell and Gene Therapy Tracker: Global CAR T-Cell Trials

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

Aug 22, 2018
The Scientist Staff

With our partners at CellTrials.org, we've developed an interactive map that displays the numbers of CAR T-cell trials taking place in countries across the world. Trials are categorized as targeting either hematologic malignancies or solid tumors. Click a country on the map to access the data on trials occurring there or scroll through the list of countries using the arrows to the left or right of the country name.

Infographic created with data compiled by CellTrials.org.

Researchers developed the first chimeric antigen receptor T cells, modified immune cells that can recognize tough-to-target cancer antigens, about three decades ago. In the past 20 years, scientists have tweaked CAR-T cells to become potent weapons against tumors. These efforts have been rewarded with several recent approvals by the US Food and Drug Administration (FDA). Last year, the FDA approved the first CAR T-cell therapy, Kymriah, which was developed by pharmaceutical giant Novartis and uses modified patient immune cells to target a particularly recalcitrant type of acute lymphoblastic leukemia. Later in 2017, the FDA granted approval to California-based Kite Pharma, which developed Yescarta, a similar CAR T-cell therapy for patients whose large B-cell lymphoma fails to respond to two other types of cancer treatments.

A number of other companies are conducting their own trials to attain regulatory approval for their own approaches to CAR T-cell therapy, which shares attributes of cell therapy, gene therapy, and immunotherapy.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.